Compare Gap Inc (GAP) vs Hims and Hers Health Inc (HIMS) Price & Performance

Gap Inc. (GAP) trades at $20.65, up 2.58% today, with a bullish technical signal supported by oscillators and key resistance at $21. The stock shows strong fundamentals with a P/E of 8.05, net income margin of 6.25%, and consistent earnings beats in recent quarters. Revenue grew to $15.09B in 2025, and operating cash flow remains robust at $1.49B. Recent news highlights digital transformation efforts and a potential turnaround in the Athleta segment.

The outlook is positive with a consensus price target of $27.00, implying 30.7% upside, though risks include ongoing legal investigations and competitive pressures. Analyst sentiment is mixed with 39.58% buy ratings, but improving profitability and undervalued metrics support a constructive view for long-term investors.

Hims & Hers Health trades at $34.78, down 1.05% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported $2.35B revenue in 2025 but faces profitability challenges with a negative net income margin of -0.56% and elevated valuation ratios including a P/E of 57.14. Recent news highlights expansion in weight-loss therapies and international markets, with Q2 2026 earnings due August 10, 2026.

The outlook remains cautiously optimistic with analyst consensus at Buy (35%) and a $33.57 price target near current levels. Key opportunities include GLP-1 therapy growth and subscriber additions, while risks involve profitability pressures, competitive threats, and reliance on regulatory approvals. The stock's performance hinges on execution in high-margin segments and cost management amid expansion.